Cortes, Jorge E <br/><br/>
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.  [electronic resource] 

 -  Leukemia  02 2019 
 - 379-389 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/s41375-018-0312-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Benzimidazoles--administration & dosage<br/>Cytarabine--administration & dosage<br/>Drug Therapy, Combination<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Leukemia, Myeloid, Acute--diagnosis<br/>Male<br/>Middle Aged<br/>Myelodysplastic Syndromes--diagnosis<br/>Phenylurea Compounds--administration & dosage<br/>Prognosis<br/>Survival Rate